Staphylococcal protein a (DrugBank: STAPHYLOCOCCAL PROTEIN A)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 63 | 特発性血小板減少性紫斑病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00571467 (ClinicalTrials.gov) | December 2007 | 10/12/2007 | Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP | An Open Label, Sequential, Dose Escalation, Repeat-dose Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRTX-100 in Adult Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) | Idiopathic Thrombocytopenic Purpura (ITP) | Drug: PRTX-100 (Staphylococcal protein A) | Protalex, Inc. | NULL | Terminated | 18 Years | N/A | All | 9 | Phase 1 | Australia;New Zealand |